跳至主要内容
临床试验/NCT02693691
NCT02693691已完成不适用

CardioMEMS European Monitoring Study for Heart Failure

Abbott Medical Devices4 个研究点 分布在 1 个国家目标入组 239 人开始时间: 2016年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
239
试验地点
4
主要终点
Freedom From Device/System Related Complications

研究概览

简要总结

The purpose of this study is to characterize the use of the CardioMEMS™ HF System when used in a real-world setting.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Indicated to receive a CardioMEMS sensor implant per the CardioMEMS™ HF System User's Manual
  • ≥ 18 years of age
  • Diagnosis of New York Heart Association (NYHA) Class III Heart Failure at the time of sensor implantation
  • Hospitalization for worsening HF, as defined in the protocol, within 12 months prior to the CardioMEMS HF System implant
  • Subjects with reduced Left Ventricular Ejection Fraction (LVEF) must be on stable Guideline Directed Medical Therapy (GDMT) as tolerated
  • Written informed consent obtained from subject

排除标准

  • Known coagulation disorders or inability to take two types of blood thinning medications for one month after the sensor is implanted
  • Subjects deemed a candidate for transplant, Ventricular Assist Device, or hospice care in the next 12 months or are otherwise not expected to be able to complete the study follow up

结局指标

主要结局

Freedom From Device/System Related Complications

时间窗: one year

This primary safety endpoints is freedom from device/system related complications (DSRCs) which is defined as an adverse event that is, or is possibly, related to the device/system (wireless pressure sensor or external electronics) and has at least one of the following characteristics: is treated with invasive means (other than intramuscular medication or right heart cauterization which is used for diagnostic purposes); results in death of the subject; or results in the explant of the device. The pre-specified goal of this endpoint was was to have a freedom from DSRC greater than 0.80 at 12 months post-implant.

Percent of Successful Pulmonary Artery Pressure Data Transmissions

时间窗: one year

Patient data transmission success is defined as the percentage of successful transmissions among attempted transmissions. All subjects who were consented and implanted with a pressure sensor regardless of study completion status are included in this analysis. All attempted data transmissions through the 12-month visit or death or withdrawal are included in the analysis. For each subject, the patient data transmission success rate (% of successful transmission) was calculated as total number of successful transmissions divided by total attempted transmissions within 12 months.

Freedom From Pressure Sensor Failure

时间窗: one year

This primary safety endpoints is freedom from pressure sensor failure greater than 0.90 at 12 months post-implant.

次要结局

  • Heart Failure Hospitalization (HFH) Rate(one year)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验